Why the study?
Does temocapril or olmesartan prevent elevation of renal Angiotensin II levels in Angiotensin I-infused rats?
Does temocapril or olmesartan prevent elevation of renal Angiotensin II levels in Angiotensin I-infused rats?
In Angiotensin I-infused rats, the AT1-receptor blocker olmesartan, but not the ACE inhibitor temocapril, suppressed the increase in renal Angiotensin II levels, suggesting an ACE inhibitor-insensitive pathway for renal Angiotensin II production.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ACE-independent renal Ang II production in rats; leaves open clinical relevance in humans.
Angiotensin II (Ang II) infusion into rats elevates local angiotensin II levels through an AT1 receptor-dependent pathway in the kidney. We examined whether treatment with an angiotensin-converting enzyme (ACE) inhibitor, temocapril, or an AT1-receptor blocker, olmesartan, prevented elevation of Ang II levels in the kidney of angiotensin I (Ang I)-infused rats. Rats were infused with Ang I (100 ng/min) and treated with temocapril (30 mg/kg per day, n = 10) or olmesartan (10 mg/kg per day, n = 9) for 4 weeks. Ang I infusion significantly elevated blood pressure compared with vehicle-infused rats (n = 6). Treatment with temocapril or olmesartan suppressed Ang I-induced hypertension. Temocapril suppressed both plasma and renal ACE activity. Ang I infusion increased Ang II content in the kidney. Interestingly, temocapril failed to reduce the level of Ang II in the kidney, while olmesartan markedly suppressed an increase in renal Ang II levels. These results suggest a limitation of temocapril and a benefit of olmesartan to inhibit the renal renin-angiotensin system and suggest the possible existence of an ACE inhibitor-insensitive pathway that increases Ang II levels in rat kidney.
No takes yet. Share an insight, caveat, or question.
Ohnishi et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: